References
1. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327-340.
2. Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.J Pediatric Infect Dis Soc. 2018;7(3):191-198.
3. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009;147(1):125-128.
4. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis. 1994;13(4):330-337.
5. Caselli D, Arico M, Michelone G, Cavanna C, Nespoli L, Burgio GR. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study.Microbiologica. 1990;13(4):347-351.
6. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. Jama. 2019;322(17):1673-1681.
7. Sawada A, Sakata N, Higuchi B, et al. [Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].Rinsho Ketsueki. 2009;50(12):1692-1699.
8. Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol.2020;38(27):3205-3216.
9. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008;46(12):1813-1821.
10. Lehrnbecher T, Schoning S, Poyer F, et al. Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study.Front Microbiol. 2019;10:681.
11. Cesaro S, Tridello G, Castagnola E, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol. 2017;99(3):240-248.
12. Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4).
13. Merkhofer RM, Klein BS. Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi. Front Cell Infect Microbiol. 2020;10:69.
14. Meryk A, Kropshofer G, Hutter J, et al. Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia. Br J Haematol.2020;191(5):816-824.
15. Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166(2):83-86.
16. Georgiadou SP, Pongas G, Fitzgerald NE, et al. Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study. Journal of the Pediatric Infectious Diseases Society. 2012;1(2):125-135.
17. Foster CE, Edwards MS, Brackett J, Schady DA, Healy CM, Baker CJ. Trichosporonosis in Pediatric Patients With a Hematologic Disorder. J Pediatric Infect Dis Soc.2018;7(3):199-204.
18. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Current opinion in pediatrics. 2020;32(1):57-66.
19. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med.2015;373(16):1541-1552.
20. Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatric blood & cancer.2014;61(3):393-400.
21. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatric blood & cancer. 2012;59(1):21-26.